Treatment of ulcerative colitis by feeding with germinated barley foodstuff

First report of a multicenter open control trial

Osamu Kanauchi, Toshihiro Suga, Masahiro Tochihara, Toshifumi Hibi, Makoto Naganuma, Terasu Homma, Hitoshi Asakura, Hiroshi Nakano, Kazuya Takahama, Yoshihide Fujiyama, Akira Andoh, Takashi Shimoyama, Nobuyuki Hida, Ken Haruma, Hideki Koga, Keichi Mitsuyama, Michio Sata, Masanobu Fukuda, Atsushi Kojima, Tadao Bamba

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Background. Germinated barley foodstuff (GBF) is a prebiotic foodstuff that effectively increases luminal butyrate production by stimulating the growth of protective bacteria. In the first pilot study, GBF has been shown to reduce both clinical activity and mucosal inflammation in ulcerative colitis (UC). The aim of this study was to investigate the efficacy of GBF in the treatment of UC in a multicenter open control trial. Methods. Eighteen patients with mildly to moderately active UC were divided into two groups using a random allocation protocol. The control group (n = 7) were given a baseline anti-inflammatory therapy for 4 weeks. In the GBF-treated group (n = 11), patients received 20-30g GBF daily, together with the baseline treatment, for 4 weeks. The response to the treatments was evaluated clinically and endoscopically. Fecal microflora were also analyzed. Results. After 4 weeks of observation, the GBF-treated group showed a significant decrease in clinical activity index scores compared with the control group (P < 0.05). No side effects related to GBF were observed. GBF therapy increased fecal concentrations of Bifidobacterium and Eubacterium limosum. Conclusions. Oral GBF therapy may have the potency to reduce clinical activity of UC. We believe that these results support the use of GBF administration as a new adjunct therapy for UC.

Original languageEnglish
Pages (from-to)67-72
Number of pages6
JournalJournal of Gastroenterology
Volume37
Issue numberSUPPL. 14
Publication statusPublished - 2002 Nov 1

Fingerprint

Hordeum
Ulcerative Colitis
Therapeutics
Eubacterium
Prebiotics
Control Groups
Bifidobacterium
Butyrates
Random Allocation
Anti-Inflammatory Agents
Observation
Inflammation
Bacteria

Keywords

  • Microflora
  • Prebiotics
  • Probiotic
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of ulcerative colitis by feeding with germinated barley foodstuff : First report of a multicenter open control trial. / Kanauchi, Osamu; Suga, Toshihiro; Tochihara, Masahiro; Hibi, Toshifumi; Naganuma, Makoto; Homma, Terasu; Asakura, Hitoshi; Nakano, Hiroshi; Takahama, Kazuya; Fujiyama, Yoshihide; Andoh, Akira; Shimoyama, Takashi; Hida, Nobuyuki; Haruma, Ken; Koga, Hideki; Mitsuyama, Keichi; Sata, Michio; Fukuda, Masanobu; Kojima, Atsushi; Bamba, Tadao.

In: Journal of Gastroenterology, Vol. 37, No. SUPPL. 14, 01.11.2002, p. 67-72.

Research output: Contribution to journalArticle

Kanauchi, O, Suga, T, Tochihara, M, Hibi, T, Naganuma, M, Homma, T, Asakura, H, Nakano, H, Takahama, K, Fujiyama, Y, Andoh, A, Shimoyama, T, Hida, N, Haruma, K, Koga, H, Mitsuyama, K, Sata, M, Fukuda, M, Kojima, A & Bamba, T 2002, 'Treatment of ulcerative colitis by feeding with germinated barley foodstuff: First report of a multicenter open control trial', Journal of Gastroenterology, vol. 37, no. SUPPL. 14, pp. 67-72.
Kanauchi, Osamu ; Suga, Toshihiro ; Tochihara, Masahiro ; Hibi, Toshifumi ; Naganuma, Makoto ; Homma, Terasu ; Asakura, Hitoshi ; Nakano, Hiroshi ; Takahama, Kazuya ; Fujiyama, Yoshihide ; Andoh, Akira ; Shimoyama, Takashi ; Hida, Nobuyuki ; Haruma, Ken ; Koga, Hideki ; Mitsuyama, Keichi ; Sata, Michio ; Fukuda, Masanobu ; Kojima, Atsushi ; Bamba, Tadao. / Treatment of ulcerative colitis by feeding with germinated barley foodstuff : First report of a multicenter open control trial. In: Journal of Gastroenterology. 2002 ; Vol. 37, No. SUPPL. 14. pp. 67-72.
@article{07cb5f7f7ef0479d80c628a334eb2f1a,
title = "Treatment of ulcerative colitis by feeding with germinated barley foodstuff: First report of a multicenter open control trial",
abstract = "Background. Germinated barley foodstuff (GBF) is a prebiotic foodstuff that effectively increases luminal butyrate production by stimulating the growth of protective bacteria. In the first pilot study, GBF has been shown to reduce both clinical activity and mucosal inflammation in ulcerative colitis (UC). The aim of this study was to investigate the efficacy of GBF in the treatment of UC in a multicenter open control trial. Methods. Eighteen patients with mildly to moderately active UC were divided into two groups using a random allocation protocol. The control group (n = 7) were given a baseline anti-inflammatory therapy for 4 weeks. In the GBF-treated group (n = 11), patients received 20-30g GBF daily, together with the baseline treatment, for 4 weeks. The response to the treatments was evaluated clinically and endoscopically. Fecal microflora were also analyzed. Results. After 4 weeks of observation, the GBF-treated group showed a significant decrease in clinical activity index scores compared with the control group (P < 0.05). No side effects related to GBF were observed. GBF therapy increased fecal concentrations of Bifidobacterium and Eubacterium limosum. Conclusions. Oral GBF therapy may have the potency to reduce clinical activity of UC. We believe that these results support the use of GBF administration as a new adjunct therapy for UC.",
keywords = "Microflora, Prebiotics, Probiotic, Ulcerative colitis",
author = "Osamu Kanauchi and Toshihiro Suga and Masahiro Tochihara and Toshifumi Hibi and Makoto Naganuma and Terasu Homma and Hitoshi Asakura and Hiroshi Nakano and Kazuya Takahama and Yoshihide Fujiyama and Akira Andoh and Takashi Shimoyama and Nobuyuki Hida and Ken Haruma and Hideki Koga and Keichi Mitsuyama and Michio Sata and Masanobu Fukuda and Atsushi Kojima and Tadao Bamba",
year = "2002",
month = "11",
day = "1",
language = "English",
volume = "37",
pages = "67--72",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "SUPPL. 14",

}

TY - JOUR

T1 - Treatment of ulcerative colitis by feeding with germinated barley foodstuff

T2 - First report of a multicenter open control trial

AU - Kanauchi, Osamu

AU - Suga, Toshihiro

AU - Tochihara, Masahiro

AU - Hibi, Toshifumi

AU - Naganuma, Makoto

AU - Homma, Terasu

AU - Asakura, Hitoshi

AU - Nakano, Hiroshi

AU - Takahama, Kazuya

AU - Fujiyama, Yoshihide

AU - Andoh, Akira

AU - Shimoyama, Takashi

AU - Hida, Nobuyuki

AU - Haruma, Ken

AU - Koga, Hideki

AU - Mitsuyama, Keichi

AU - Sata, Michio

AU - Fukuda, Masanobu

AU - Kojima, Atsushi

AU - Bamba, Tadao

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Background. Germinated barley foodstuff (GBF) is a prebiotic foodstuff that effectively increases luminal butyrate production by stimulating the growth of protective bacteria. In the first pilot study, GBF has been shown to reduce both clinical activity and mucosal inflammation in ulcerative colitis (UC). The aim of this study was to investigate the efficacy of GBF in the treatment of UC in a multicenter open control trial. Methods. Eighteen patients with mildly to moderately active UC were divided into two groups using a random allocation protocol. The control group (n = 7) were given a baseline anti-inflammatory therapy for 4 weeks. In the GBF-treated group (n = 11), patients received 20-30g GBF daily, together with the baseline treatment, for 4 weeks. The response to the treatments was evaluated clinically and endoscopically. Fecal microflora were also analyzed. Results. After 4 weeks of observation, the GBF-treated group showed a significant decrease in clinical activity index scores compared with the control group (P < 0.05). No side effects related to GBF were observed. GBF therapy increased fecal concentrations of Bifidobacterium and Eubacterium limosum. Conclusions. Oral GBF therapy may have the potency to reduce clinical activity of UC. We believe that these results support the use of GBF administration as a new adjunct therapy for UC.

AB - Background. Germinated barley foodstuff (GBF) is a prebiotic foodstuff that effectively increases luminal butyrate production by stimulating the growth of protective bacteria. In the first pilot study, GBF has been shown to reduce both clinical activity and mucosal inflammation in ulcerative colitis (UC). The aim of this study was to investigate the efficacy of GBF in the treatment of UC in a multicenter open control trial. Methods. Eighteen patients with mildly to moderately active UC were divided into two groups using a random allocation protocol. The control group (n = 7) were given a baseline anti-inflammatory therapy for 4 weeks. In the GBF-treated group (n = 11), patients received 20-30g GBF daily, together with the baseline treatment, for 4 weeks. The response to the treatments was evaluated clinically and endoscopically. Fecal microflora were also analyzed. Results. After 4 weeks of observation, the GBF-treated group showed a significant decrease in clinical activity index scores compared with the control group (P < 0.05). No side effects related to GBF were observed. GBF therapy increased fecal concentrations of Bifidobacterium and Eubacterium limosum. Conclusions. Oral GBF therapy may have the potency to reduce clinical activity of UC. We believe that these results support the use of GBF administration as a new adjunct therapy for UC.

KW - Microflora

KW - Prebiotics

KW - Probiotic

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=0036853845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036853845&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 67

EP - 72

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - SUPPL. 14

ER -